THE 30TH SYMPOSIUM

OVERCOMING THE INNATE RESISTANCE OF CANCER TO THERAPY

Scientific Committee: Head:David Livingston, Co-Chairs: Alberto Bardelli, Massimo Loda, Pier Paolo Pandolfi, Stefano Piccolo. Trento, June 25-26, 2018.


FOCUS AND GOALS


Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small fraction of patients undergo extended therapeutic responses. For prostate cancer patients whose tumors develop anti-androgen therapy resistance, further therapy has largely failed. And for cancers like Glioblastoma, pancreatic cancer, mesothelioma, small cell cancer and chemotherapy and marrow transplant-resistant acute myelogenous leukemia, a pathway to therapeutic success is not yet apparent. The thrust of this meeting will be to explore the molecular and biological sources of historical therapeutic resistance in these cancers and to assess the most promising opportunities for overcoming it.

The 30th Symposium was marked by a record of attendance (220 participants) and poster presentations (45), compared to the previous years. This was partly due to the increased popularity of the Pezcoller Symposia, but mostly to the spectacular program and faculty put together by the Symposium Scientific Committee, headed by dr. Livingston. In addition to the best international experts involved this year Symposium was further enriched by the keynote lecture given by the Nobel Laureate Harold Varmus.
Pezcoller President Galligioni welcoming partecipants to the 30th Symposium, 25 June, 2018
Chairman of the Pezcoller Symposia David Livingston, introducing focus and goal of the 30th Symposium
Harold Varmus (Nobel 1989) at the keynote lecture, opening the 30th Pezcoller Symposium (June 25-26, 2018)
Attendants at the 30th Pezcoller Symposium
unchecked checked